Literature DB >> 23883673

The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Jennifer M Sasser1.   

Abstract

Emerging evidence supports a potential therapeutic role of relaxin in fibrotic diseases, including chronic kidney disease. Relaxin is a pleiotropic hormone, best characterized for its role in the reproductive system; however, recent studies have demonstrated a role of relaxin in the cardiorenal system. Both relaxin and its receptor, RXFP1, are expressed in the kidney, and relaxin has been shown to play a role in renal vasodilation, in sodium excretion, and as an antifibrotic agent. Together, these findings suggest that the kidney is a target organ of relaxin. Therefore, the purpose of this review is to describe the functional and structural impacts of relaxin treatment on the kidney and to discuss evidence that relaxin prevents disease progression in several experimental models of kidney disease. In addition, this review will present potential mechanisms that are involved in the therapeutic actions of relaxin.

Entities:  

Keywords:  glomerular sclerosis; matrix metalloproteinases; nitric oxide; oxidative stress; renal function; transforming growth factor-β; tubulointersitital fibrosis

Mesh：

Substances：

Year:  2013        PMID： 23883673      PMCID： PMC3763042          DOI： 10.1152/ajpregu.00528.2012

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN： 0363-6119            Impact factor:   3.619


  85 in total

1.  Impaired nipple development and parturition in LGR7 knockout mice.

Authors:  Magda A M Krajnc-Franken; Ad J M van Disseldorp; Jasper E Koenders; Sietse Mosselman; Marcel van Duin; Jan A Gossen
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

Review 2.  Emerging role of relaxin in renal and cardiovascular function.

Authors:  Kirk P Conrad; Jacqueline Novak
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-08       Impact factor: 3.619

Review 3.  Relaxin's physiological roles and other diverse actions.

Authors:  O David Sherwood
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

4.  Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts.

Authors:  E N Unemori; E P Amento
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

5.  Preparation of biologically active 32P-labeled human relaxin. Displaceable binding to rat uterus, cervix, and brain.

Authors:  P L Osheroff; V T Ling; R L Vandlen; M J Cronin; J A Lofgren
Journal:  J Biol Chem       Date:  1990-06-05       Impact factor: 5.157

6.  Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries.

Authors:  Arundhathi Jeyabalan; Jacqueline Novak; Lee A Danielson; Laurie J Kerchner; Shannon L Opett; Kirk P Conrad
Journal:  Circ Res       Date:  2003-10-30       Impact factor: 17.367

7.  Chronic decrease of blood pressure by rat relaxin in spontaneously hypertensive rats.

Authors:  J St-Louis; G Massicotte
Journal:  Life Sci       Date:  1985-10-07       Impact factor: 5.037

8.  Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.

Authors:  Chrishan S Samuel; Chongxin Zhao; Courtney P Bond; Tim D Hewitson; Edward P Amento; Roger J Summers
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

9.  Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro.

Authors:  Rosemary Masterson; Tim D Hewitson; Kristen Kelynack; Marina Martic; Laura Parry; Ross Bathgate; Ian Darby; Gavin Becker
Journal:  Nephrol Dial Transplant       Date:  2004-03       Impact factor: 5.992

10.  Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo.

Authors:  Chrishan S Samuel; Elaine N Unemori; Ishanee Mookerjee; Ross A D Bathgate; Sharon L Layfield; John Mak; Geoffrey W Tregear; Xiao-Jun Du
Journal:  Endocrinology       Date:  2004-05-20       Impact factor: 4.736
View more
  9 in total

1.  Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.

Authors:  Victoria L Wolf; Taylor L Phillips; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

2.  Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α).

Authors:  Sudhir Singh; Ronda L Simpson; Robert G Bennett
Journal:  J Biol Chem       Date:  2014-11-11       Impact factor: 5.157

3.  Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension.

Authors:  Jennifer M Sasser; Mark W Cunningham; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2014-10-08

4.  Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia.

Authors:  Jose A Santiago-Font; Lorena M Amaral; Jessica Faulkner; Tarek Ibrahim; Venkata Ramana Vaka; Mark W Cunningham; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-09-14       Impact factor: 3.619

Review 5.  Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies.

Authors:  Wenshan Lv; George W Booz; Fan Fan; Yangang Wang; Richard J Roman
Journal:  Front Physiol       Date:  2018-02-16       Impact factor: 4.566

Review 6.  Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta.

Authors:  Manoj Kumar Jena; Neeta Raj Sharma; Matthew Petitt; Devika Maulik; Nihar Ranjan Nayak
Journal:  Biomolecules       Date:  2020-06-24

Review 7.  The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.

Authors:  Ting-Yun Chen; Xiaoyun Li; Ching-Hsia Hung; Harinath Bahudhanapati; Jiangning Tan; Daniel J Kass; Yingze Zhang
Journal:  Mol Genet Genomic Med       Date:  2020-02-26       Impact factor: 2.183

8.  Identification of a distal RXFP1 gene enhancer with differential activity in fibrotic lung fibroblasts involving AP-1.

Authors:  Ting-Yun Chen; Xiaoyun Li; Gillian C Goobie; Ching-Hsia Hung; Tin-Kan Hung; Kyle Hamilton; Harinath Bahudhanapati; Jiangning Tan; Daniel J Kass; Yingze Zhang
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

9.  New targets for renal interstitial fibrosis: relaxin family peptide receptor 1-angiotensin type 2 receptor heterodimers.

Authors:  Jennifer M Sasser
Journal:  Kidney Int       Date:  2014-07       Impact factor: 10.612
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.